Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Natural Product (NP) Details

General Information of the NP (ID: NP4822)
Name
Malic acids
Species Origin Actinidia chinensis ...     Click to Show/Hide
Actinidia chinensis
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Ericales
Family: Actinidiaceae
Genus: Actinidia
Species: Actinidia chinensis
Disease Hypertension [ICD-11: BA00] Phase 3 [1]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Trimetazidine      Angina pectoris     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model The study was carried out on 40 male Wistar rats (230-250 g).
                    Experimental
                    Result(s)
A mixture of mitochondrial substrates of succinic and malic acids more effectively than antihypoxant trimetazidine prevented functional and metabolic disorders in rat myocardium during acute ischemia.
References
Reference 1 ClinicalTrials.gov (NCT01652001) Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Reference 2 Cardioprotective effects of trimetazidine and a combination of succinic and malic acids in acute myocardial ischemia. Bull Exp Biol Med. 2008 Aug;146(2):218-22.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China